RLMD
Relmada Therapeutics Inc
NASDAQ: RLMD · HEALTHCARE · BIOTECHNOLOGY
$7.52
+2.04% today
Updated 2026-04-30
Market cap
$759.40M
P/E ratio
—
P/S ratio
9,001.90x
EPS (TTM)
$-1.45
Dividend yield
—
52W range
$0 – $8
Volume
2.1M
Relmada Therapeutics Inc (RLMD) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2012 | 2013 | 2014 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $18354.00 | $25.76M | $25.76M | $24.39M | $24.39M | $10.24M | $2.84M | $3.05M | $117.14M | $118.19M | $223.33M | $152.91M | $97.55M | $45.82M |
| Cash & equivalents | $8949.00 | $25.56M | $25.56M | $22.47M | $22.47M | $8.50M | $1.71M | $2.24M | $36.28M | $2.50M | $44.44M | $5.40M | $4.09M | $3.86M |
| Current assets | $18354.00 | $25.74M | $25.74M | $23.97M | $23.97M | $9.30M | $2.47M | $2.74M | $116.94M | $118.07M | $223.30M | $152.87M | $97.51M | $45.80M |
| Total liabilities | $6996.00 | $26.87M | $26.87M | $15.58M | $15.58M | $3.20M | $1.38M | $8.56M | $1.46M | $12.60M | $15.06M | $12.47M | $12.19M | $10.30M |
| Current liabilities | $6996.00 | $26.77M | $26.77M | $15.58M | $15.58M | $3.06M | $1.38M | $5.90M | $1.46M | $12.60M | $15.06M | $12.47M | $12.19M | $10.29M |
| Long-term debt | — | — | — | — | — | — | $2.66M | — | — | — | — | — | — | — |
| Shareholder equity | $11358.00 | $-55.28M | $-1.11M | $8.81M | $8.81M | $7.04M | $1.46M | $-5.51M | $115.68M | $105.58M | $208.26M | $140.44M | $85.36M | $35.52M |
| Retained earnings | $-12142.00 | $-55.32M | $-55.32M | $-76.12M | $-76.12M | $-79.10M | $-85.38M | $-94.34M | $-119.86M | $-179.32M | $-305.07M | $-462.11M | $-560.90M | $-640.88M |
| Accounts receivable | — | — | — | $82000.00 | $82000.00 | $263342.00 | $291916.00 | $72103.00 | $73091.00 | $79457.00 | $86377.00 | $512432.00 | — | — |
| Inventory | $6405.00 | $3169.00 | — | — | $1.35M | $534800.00 | $472500.00 | $426900.00 | $459000.00 | $903200.00 | $11.30M | $4.04M | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | — | — |